Cargando…

Targeting BRAF(V600E) with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer

PURPOSE. B-Raf(V600E) may play a role in the progression from papillary thyroid cancer to anaplastic thyroid cancer (ATC). We tested the effects of a highly selective B-Raf(V600E) inhibitor, PLX4720, on proliferation, migration, and invasion both in human thyroid cancer cell lines (8505c(B-RafV600E)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nucera, Carmelo, Nehs, Matthew A., Nagarkatti, Sushruta S., Sadow, Peter M., Mekel, Michal, Fischer, Andrew H., Lin, Paul S., Bollag, Gideon E., Lawler, Jack, Hodin, Richard A., Parangi, Sareh
Formato:	Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2011
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073446/ https://www.ncbi.nlm.nih.gov/pubmed/21355020 http://dx.doi.org/10.1634/theoncologist.2010-0317

Ejemplares similares

The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010)

The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors
por: Coperchini, Francesca, et al.
Publicado: (2019)

Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance
por: Oikonomou, Eftychia, et al.
Publicado: (2011)

ZAK Inhibitor PLX4720 Promotes Extrusion of Transformed Cells via Cell Competition
por: Maruyama, Takeshi, et al.
Publicado: (2020)

Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment
por: Duquette, Mark, et al.
Publicado: (2013)

Corrigendum: Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells With BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment
por: Duquette, Mark, et al.
Publicado: (2020)

Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer
por: Rohde, Sarah, et al.
Publicado: (2017)

Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer
por: Borre, Pierre Vanden, et al.
Publicado: (2014)

Adaptive up-regulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
por: Basile, Kevin J., et al.
Publicado: (2011)

Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
por: Su, Xi, et al.
Publicado: (2021)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
por: Jenkins, Molly H., et al.
Publicado: (2015)

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
por: Rubinstein, Jill C, et al.
Publicado: (2010)

Differential sensitivity of melanoma cell lines with BRAF(V600E )mutation to the specific Raf inhibitor PLX4032
por: Søndergaard, Jonas N, et al.
Publicado: (2010)

Induced cross-resistance of BRAF(V600E) melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment
por: Erdmann, Sarah, et al.
Publicado: (2019)

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010)

HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF(V600E) Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
por: Furfaro, Anna Lisa, et al.
Publicado: (2022)

Clinical Outcome, Role of BRAF(V600E), and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?
por: Nucera, Carmelo, et al.
Publicado: (2012)

Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
por: Zhang, Honglai, et al.
Publicado: (2018)

Effects of Withdrawal Rate on the Microstructure of Directionally Solidified GH4720Li Superalloys
por: Qu, Jinglong, et al.
Publicado: (2019)

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
por: Tutuka, Candani S. A., et al.
Publicado: (2017)

Extracellular Matrix Proteins Modulate Antimigratory and Apoptotic Effects of Doxorubicin
por: Said, Georges, et al.
Publicado: (2012)

Cytotoxic and Antimigratory Activities of Phenolic Compounds from Dendrobium brymerianum
por: Klongkumnuankarn, Pornprom, et al.
Publicado: (2015)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAF(V600E) patient-derived papillary thyroid carcinoma preclinical model
por: Duquette, Mark, et al.
Publicado: (2015)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

3D collagen type I matrix inhibits the antimigratory effect of doxorubicin
por: Millerot-Serrurot, Emilie, et al.
Publicado: (2010)

The Cytotoxic and Antimigratory Activity of Brazilin-Doxorubicin on MCF-7/HER2 Cells
por: Jenie, Riris Istighfari, et al.
Publicado: (2018)

Cytochalasans from the Endophytic Fungus Phomopsis sp. shj2 and Their Antimigratory Activities
por: Yan, Bing-Chao, et al.
Publicado: (2022)

Synergistic Cytotoxic and Antimigratory Effect of Brazilein and Doxorubicin on HER2-Overexpressing Cells
por: Handayani, Sri, et al.
Publicado: (2022)

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E)
por: Antonello, Zeus A., et al.
Publicado: (2017)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

Proapoptotic and Antimigratory Effects of Pseudevernia furfuracea and Platismatia glauca on Colon Cancer Cell Lines
por: Šeklić, Dragana S., et al.
Publicado: (2018)

Antiproliferative and antimigratory activities of bisphosphonates in human breast cancer cell line MCF-7
por: Buranrat, Benjaporn, et al.
Publicado: (2019)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_maaespj0tuuq3eh929cqmug2j2